Last updated: 18 June 2024 at 6:06pm EST

Yuval Cohen Net Worth




The estimated Net Worth of Yuval Cohen is at least 11 百万$ dollars as of 14 June 2024. Mr. Cohen owns over 63,358 units of Corbus Pharmaceuticals Inc stock worth over 4,070,319$ and over the last 10 years he sold CRBP stock worth over 2,950,582$. In addition, he makes 4,001,510$ as Chief Executive Officer、 Director at Corbus Pharmaceuticals Inc.

Mr. Cohen CRBP stock SEC Form 4 insiders trading

Yuval has made over 32 trades of the Corbus Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 63,358 units of CRBP stock worth 2,950,582$ on 14 June 2024.

The largest trade he's ever made was selling 63,358 units of Corbus Pharmaceuticals Inc stock on 14 June 2024 worth over 2,950,582$. On average, Yuval trades about 4,450 units every 81 days since 2014. As of 14 June 2024 he still owns at least 77,221 units of Corbus Pharmaceuticals Inc stock.

You can see the complete history of Mr. Cohen stock trades at the bottom of the page.





Yuval Cohen biography

Yuval Cohen serves as Chief Executive Officer, Director of the Company. Dr. Cohen has served as our Chief Executive Officer and as a director since April 11, 2014. Dr. Cohen joined Corbus Pharmaceuticals, Inc. (formerly JB Therapeutics, Inc.), our wholly-owned subsidiary, as its Chief Executive Officer in July 2013. Prior to joining Corbus Pharmaceuticals, Inc., he was the President and co-founder of Celsus Therapeutics PLC (“Celsus”) (Nasdaq CM: CLTX) from 2005 until February 2013, and as Senior Vice President from February 2013 until June 2013. Dr. Cohen was also a board member of Celsus until December 2013. Starting as a small startup with seed financing, under Dr. Cohen’s leadership, Celsus developed five novel anti-inflammatory drug candidates with two reaching Phase IIb stages focusing on allergies and autoimmune diseases of the skin (eczema), airways (cystic fibrosis and hay fever), digestive tract (inflammatory bowel disease) and eye (conjunctivitis). Dr. Cohen participated in all stages of the pre-clinical and clinical development from project management to interactions with regulatory bodies and with the investment community in fundraising. Apart from his industry experience, he is also the author of a number of peer-reviewed papers and reviews as well as listed inventor on a number of patents. Dr. Cohen holds a BSc (Hons) in microbiology and biochemistry from University of Cape Town, South Africa, and has a Ph.D., summa cum laude, from the Curie Institute of Cancer Research in Paris and the University of Paris V. Dr. Cohen was selected as a director because of his business and leadership experience in the biopharmaceutical sector, as well as a result of having served as a director since our inception.

What is the salary of Yuval Cohen?

As the Chief Executive Officer、 Director of Corbus Pharmaceuticals Inc, the total compensation of Yuval Cohen at Corbus Pharmaceuticals Inc is 4,001,510$. There are no executives at Corbus Pharmaceuticals Inc getting paid more.



How old is Yuval Cohen?

Yuval Cohen is 57, he's been the Chief Executive Officer、 Director of Corbus Pharmaceuticals Inc since . There are 6 older and 5 younger executives at Corbus Pharmaceuticals Inc. The oldest executive at Corbus Pharmaceuticals Holdings Inc is Avery Catlin, 72, who is the Independent Director.

What's Yuval Cohen's mailing address?

Yuval's mailing address filed with the SEC is C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD, MA, 02062.

Insiders trading at Corbus Pharmaceuticals Inc

Over the last 10 years, insiders at Corbus Pharmaceuticals Inc have traded over 3,643,182$ worth of Corbus Pharmaceuticals Inc stock and bought 2,676,074 units worth 50,292,165$ . The most active insiders traders include Asset Management, Lp Chen B...Asset Management, Lp Cormor...Sean F. Moran. On average, Corbus Pharmaceuticals Inc executives and independent directors trade stock every 21 days with the average trade being worth of 1,059,576$. The most recent stock trade was executed by Sean F. Moran on 14 June 2024, trading 18,043 units of CRBP stock currently worth 233,837$.



What does Corbus Pharmaceuticals Inc do?

corbus pharmaceuticals holdings, inc. (nasdaq: crbp) is a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases with clear unmet needs. the company's lead product candidate, resunab™, is a first-in-class, oral anti-inflammatory drug that acts to resolve inflammation through an endogenous pathway. resunab is scheduled to commence three phase 2 clinical trials in 2015 for the treatment of cystic fibrosis, diffuse systemic sclerosis ("scleroderma") and dermatomyositis, three diseases in which inflammation contributes to disease progression. resunab also has the potential to treat additional rare, inflammatory diseases.



What does Corbus Pharmaceuticals Inc's logo look like?

Corbus Pharmaceuticals Holdings Inc logo

Complete history of Mr. Cohen stock trades at Corbus Pharmaceuticals Inc

日付
#
会社
インサイダー
取引
取引
株式 1株当たりの株価 合計金額 その後の株式数 ソース
14 Jun 2024 Yuval Cohen
Chief Executive Officer
販売 63,358 46.57$ 2,950,582$
14 Jun 2024
77,221
26 Jan 2024 Yuval Cohen
Chief Executive Officer
オプション行使 7,179 4.97$ 35,680$
26 Jan 2024
7,179
10 Aug 2022 Yuval Cohen
Chief Executive Officer
購入する 3,800 0.26$ 988$
10 Aug 2022
98,230
16 May 2022 Yuval Cohen
Chief Executive Officer
購入する 10,500 0.25$ 2,625$
16 May 2022
94,430
9 Mar 2022 Yuval Cohen
Chief Executive Officer
購入する 8,600 0.37$ 3,182$
9 Mar 2022
83,930
11 Nov 2020 Yuval Cohen
Chief Executive Officer
購入する 4,240 1.21$ 5,130$
11 Nov 2020
75,330
17 Mar 2020 Yuval Cohen
Chief Executive Officer
購入する 4,300 3.49$ 15,007$
17 Mar 2020
71,090
12 Nov 2019 Yuval Cohen
Chief Executive Officer
購入する 1,430 4.26$ 6,092$
12 Nov 2019
66,790
12 Aug 2019 Yuval Cohen
Chief Executive Officer
購入する 1,175 6.06$ 7,121$
12 Aug 2019
65,360
13 May 2019 Yuval Cohen
Chief Executive Officer
購入する 995 6.99$ 6,955$
13 May 2019
64,185
14 Mar 2019 Yuval Cohen
Chief Executive Officer
購入する 1,530 6.49$ 9,930$
14 Mar 2019
63,190
15 May 2018 Yuval Cohen
Chief Executive Officer
購入する 1,725 5.85$ 10,091$
15 May 2018
61,660
14 Mar 2018 Yuval Cohen
Chief Executive Officer
購入する 1,160 6.89$ 7,992$
14 Mar 2018
59,935
10 Nov 2017 Yuval Cohen
Chief Executive Officer
購入する 1,000 7.17$ 7,170$
10 Nov 2017
58,775
11 Aug 2017 Yuval Cohen
Chief Executive Officer
購入する 1,695 6.00$ 10,170$
11 Aug 2017
57,775
11 May 2017 Yuval Cohen
Chief Executive Officer
購入する 3,250 6.01$ 19,533$
11 May 2017
56,080
16 Mar 2017 Yuval Cohen
Chief Executive Officer
オプション行使 20,000 1.00$ 20,000$
16 Mar 2017
52,830
22 Nov 2016 Yuval Cohen
Chief Executive Officer
購入する 1,340 7.64$ 10,238$
22 Nov 2016
12,830
17 Aug 2016 Yuval Cohen
Chief Executive Officer
オプション行使 20,000 1.00$ 20,000$
17 Aug 2016
31,490
17 Aug 2016 Yuval Cohen
Chief Executive Officer
オプション行使 20,000 1.00$ 20,000$
17 Aug 2016
31,490
6 Jun 2016 Yuval Cohen
Chief Executive Officer
購入する 1,500 3.34$ 5,010$
6 Jun 2016
11,490
6 Jun 2016 Yuval Cohen
Chief Executive Officer
購入する 1,500 3.34$ 5,010$
6 Jun 2016
11,490
18 May 2016 Yuval Cohen
Chief Executive Officer
購入する 2,125 2.40$ 5,100$
18 May 2016
9,990
18 May 2016 Yuval Cohen
Chief Executive Officer
購入する 2,125 2.40$ 5,100$
18 May 2016
9,990
23 Nov 2015 Yuval Cohen
Chief Executive Officer
購入する 535 1.76$ 942$
23 Nov 2015
6,835
13 Nov 2015 Yuval Cohen
Chief Executive Officer
購入する 850 1.73$ 1,471$
13 Nov 2015
6,300
24 Aug 2015 Yuval Cohen
Chief Executive Officer
購入する 550 1.95$ 1,073$
24 Aug 2015
5,450
17 Aug 2015 Yuval Cohen
Chief Executive Officer
購入する 2,100 1.92$ 4,032$
17 Aug 2015
4,900
15 Jun 2015 Yuval Cohen
Chief Executive Officer
購入する 900 3.28$ 2,952$
15 Jun 2015
2,800
17 Dec 2014 Yuval Cohen
Chief Executive Officer
購入する 400 3.66$ 1,464$
17 Dec 2014
1,900
4 Dec 2014 Yuval Cohen
Chief Executive Officer
購入する 500 3.30$ 1,650$
4 Dec 2014
1,500
3 Dec 2014 Yuval Cohen
Chief Executive Officer
購入する 1,000 3.20$ 3,200$
3 Dec 2014
1,000


Corbus Pharmaceuticals Inc executives and stock owners

Corbus Pharmaceuticals Inc executives and other stock owners filed with the SEC include: